Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Animals
Antineoplastic Agents
/ therapeutic use
Dog Diseases
/ blood
Dogs
Double-Blind Method
Etoposide
/ analogs & derivatives
Female
Fibrin Fibrinogen Degradation Products
/ metabolism
Lymphoma, Non-Hodgkin
/ blood
Male
Organophosphorus Compounds
/ therapeutic use
Podophyllotoxin
/ analogs & derivatives
Prognosis
Thymidine Kinase
/ genetics
D-dimer
dog
lymphoma
prognostic marker
survival
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
03
2020
revised:
11
06
2020
accepted:
13
06
2020
pubmed:
10
7
2020
medline:
23
9
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Pretreatment D-dimer levels have been reported to predict survival in several types of malignancies in human patients. The objective of this study was to evaluate the prognostic value of pretreatment D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma (NHL). In a prospective, randomized, double-blind study of F14512 vs etoposide phosphate, we assessed the prognostic value of pretreatment plasma D-dimer level in 48 client-owned dogs diagnosed with intermediate to high-grade NHL. The correlation between pretreatment plasma D-dimer level and various clinical features, progression-free survival (PFS) and overall survival (OS) was analysed. The median value of pretreatment plasma D-dimer level was 0.4 μg/mL (range: 0.1-14.3 μg/mL). High pretreatment plasma D-dimer level (>0.5 μg/mL) was detected in 44% (21/48) of dogs. High D-dimer levels were not correlated with naive vs relapsed lymphoma, clinical stage, substage, immunophenotype or treatment group. D-dimer levels >0.5 μg/mL were significantly associated with inferior median PFS (54 vs 104 days, P = .011) and OS (93 vs 169 days, P = .003). In the multivariate analysis, high D-dimer levels remained an independent predictor for worse PFS (HR: 3.21, 95% CI: 1.57-6.56, P = .001) and OS (HR: 3.87, 95% CI: 1.88-7.98; P < .001). This study suggests that pretreatment plasma D-dimer level can serve as a predictor of prognosis in dogs with intermediate to high-grade NHL. Further studies are warranted to confirm these findings.
Substances chimiques
Antineoplastic Agents
0
F14512
0
Fibrin Fibrinogen Degradation Products
0
Organophosphorus Compounds
0
fibrin fragment D
0
etoposide phosphate
528XYJ8L1N
Etoposide
6PLQ3CP4P3
Thymidine Kinase
EC 2.7.1.21
thymidine kinase 1
EC 2.7.1.21
Podophyllotoxin
L36H50F353
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-52Subventions
Organisme : BPI-France
Organisme : CNRS - UMR 5089
Organisme : Pierre Fabre Research Institute
Organisme : Oncovet-Clinical-Research
Informations de copyright
© 2020 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Ponce F, Marchal T, Magnol JP, et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol. 2010;47(3):414-433.
Seelig DM, Avery AC, Ehrhart EJ, Linden MA. The comparative diagnostic features of canine and human lymphoma. Vet Sci. 2016;3(2):11.
Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol. 2014;159(3-4):192-201.
Teske E, Van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc. 1994;205(12):1722-1728.
Marconato L, Polton GA, Sabattini S, et al. Conformity and controversies in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature. Vet Comp Oncol. 2017;15(3):1029-1040.
Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med. 1993;7(5):289-295.
Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med A Physiol Pathol Clin Med. 2002;49(8):419-424.
Simon D, Moreno SN, Hirschberger J, et al. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc. 2008;232(6):879-885.
Beaver LM, Strottner G, Klein MK. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008). J Am Vet Med Assoc. 2010;237(9):1052-1055.
Rebhun RB, Kent MS, Borrofka SA, Frazier S, Skorupski K, Rodriguez CO. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma. Vet Comp Oncol. 2011;9(1):38-44.
Marconato L, Stefanello D, Valenti P, et al. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc. 2011;238(4):480-485.
Williams MJ, Avery AC, Lana SE, Hillers KR, Bachand AM, Avery PR. Canine lymphoproliferative disease characterized by lymphocytosis: immunophenotypic markers of prognosis. J Vet Intern Med. 2008;22(3):596-601.
Flood-Knapik KE, Durham AC, Gregor TP, Sánchez MD, Durney ME, Sorenmo KU. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol. 2013;11(4):272-286.
Valli VE, Kass PH, San Myint M, Scott F. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Vet Pathol. 2013;50(5):738-748.
Ponce F, Magnol JP, Ledieu D, et al. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J. 2004;167(2):158-166.
Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med. 2006;20(1):136-143.
Rassnick KM, Moore AS, Collister KE, et al. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. J Vet Intern Med. 2009;23(2):317-322.
Keller SM, Vernau W, Hodges J, et al. Hepatosplenic and hepatocytotropic T-cell lymphoma: two distinct types of T-cell lymphoma in dogs. Vet Pathol. 2013;50(2):281-290.
Mealey KL, Bentjen SA, Gay JM, Hosick HL. Dexamethasone treatment of a canine, but not human, tumour cell line increases chemoresistance independent of P-glycoprotein and multidrug resistance-related protein expression. Vet Comp Oncol. 2003;1(2):67-75.
Vail DM, Kravis LD, Kisseberth WC, Ogilvie GK, Volk LM. Application of rapid CD3 immunophenotype analysis and argyrophilic nucleolar organizer region (AgNOR) frequency to fine needle aspirate specimens from dogs with lymphoma. Vet Clin Pathol. 1997;26(2):66-69.
Renwick MG, Argyle DJ, Long S, Nixon C, Gault EA, Nasir L. Telomerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: correlation with Ki67 immunoreactivity. Vet Comp Oncol. 2006;4(3):141-150.
Zanatta R, Abate O, D'Angelo A, Miniscalco B, Mannelli A. Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma. Vet Res Commun. 2003;27(suppl 1):449-452.
Marconato L, Crispino G, Finotello R, Mazzotti S, Zini E. Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma. J Am Vet Med Assoc. 2010;236(9):969-974.
Nielsen L, Toft N, Eckersall PD, Mellor DJ, Morris JS. Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma. J Vet Intern Med. 2007;21(6):1231-1236.
Fontaine SJ, McCulloch E, Eckersall PD, Haining H, Patterson Kane JC, Morris JS. Evaluation of the modified Glasgow prognostic score to predict outcome in dogs with newly diagnosed lymphoma. Vet Comp Oncol. 2017;15(4):1513-1526.
Von Euler H, Einarsson R, Olsson U, Lagerstedt AS, Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004;18(5):696-702.
De Buyzere M, Philippé J, Duprez D, Baele G, Clement DL. Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol. 1993;43(2):91-94.
Batschauer APB, Figueiredo CP, Bueno EC, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-1272.
Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. OCL. 2012;83(1):10-15.
Blackwell K, Hurwitz H, Liebérman G, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101(1):77-82.
Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol. 2013;39(9):951-956.
Fukumoto K, Taniguchi T, Usami N, et al. Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer. Surg Today. 2015;45(1):63-67.
Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer. J Int Med Res. 2019;47(1):215-224.
Liu L, Zhang X, Yan B, et al. Elevated plasma D-dimer levels correlate with long term survival of gastric cancer patients. PLoS ONE. 2014;9(3):e90547.
Go SI, Lee MJ, Lee WS, et al. D-dimer can serve as a prognostic and predictive biomarker for metastatic gastric cancer treated by chemotherapy. Medicine (Baltimore). 2015;94(30):e951.
Nakamura K, Nakayama K, Ishikawa M, et al. High pre-treatment plasma D-dimer level as a potential prognostic biomarker for cervical carcinoma. Anticancer Res. 2016;36(6):2933-2938.
Liu B, Li B, Zhou P, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). Clin Chim Acta. 2018;482:191-198.
Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5(suppl 1):246-254.
Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res. 2010;125(suppl 2):S36-S38.
Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18(4):353-372.
Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29):4834-4838.
Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878-2887.
Kristensen AT, Wiinberg B, Jessen LR, Andreasen E, Jensen AL. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. J Vet Intern Med. 2008;22(1):140-147.
Andreasen EB, Tranholm M, Wiinberg B, Markussen B, Kristensen AT. Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Vet Scand. 2012;54:3.
Font C, de la Fuente C, Pumarola M, et al. Canine intracranial meningiomas: Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers. Vet J. 2015;206(3):426-428.
Serres F, Tierny D, Hidalgo A, Haelewyn C, Marescaux L. Assessment and prognostic implication of D-dimer value in dogs with miscellaneous tumors: a prospective study of 149 dogs. In: Proceedings of the 2011 Annual Congress of the European Society of Veterinary Oncology (ESVONC), Glasgow, UK, 24-26th March, 2011.
Boyé P, Floch F, Serres F, et al. Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma. Oncotarget. 2020;11:671-686.
Marconato L, Martini V, Aresu L, et al. Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: prognostic significance and proposal of a cut-off value. Vet J. 2013;197(3):776-781.
Fournel-Fleury C, Magnol JP, Bricaire P, et al. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol. 1997;117(1):35-59.
Tierny D, Serres F, Segaoula Z, et al. Phase I clinical pharmacology study of F14512, a new polyamine-vectorized anticancer drug, in naturally occurring canine lymphoma. Clin Cancer Res. 2015;21(23):5314-5323.
Dewhurst E, Cue S, Crawford E, Papasouliotis K. A retrospective study of canine D-dimer concentrations measured using an immunometric « Point-of-Care » test. J Small Anim Pract. 2008;49(7):344-348.
Boyé P, Floch F, Serres F, et al. Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma. J Vet Intern Med. 2019;33(4):1728-1739.
Boyé P, Serres F, Marescaux L, et al. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma. PLoS ONE. 2017;12(5):e0177486.
Vail DM, Michels GM, Khanna C, Selting KA, London CA, Veterinary Cooperative Oncology Group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28-37.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57(1):289-300.
Bi X, Wang L, Zhang W, et al. High pretreatment D-dimer levels correlate with adverse clinical features and predict poor survival in patients with natural killer/T-cell lymphoma. PLoS ONE. 2016;11(3):e0152842.
Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(3):170-175.
Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study. J Clin Oncol. 2009;27(25):4124-4129.